New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:17 EDTMDTMedtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint
Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use